Drug combinations comprising KRAS G12C inhibitors and the FAK inhibitor IN10018 showed promising synergistic effects against diverse cancer cells and multiple cancer models, including NSCLC, CRC, and pancreatic cancer. This evidence concerns the gene PTK2 and pancreatic neoplasm.